Background Thiopurines are used for many cancers, including acute lymphoblastic leukemia (ALL). Patients with an inherited host defect in thiopurine methyltransferase (TPMT) are at high risk for lifethreatening toxicity if treated with conventional dosages, but the impact on antileukemic efficacy is less clear.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. The treatment regimen consists of several chemotherapeutics, including the thiopurine 6-mercaptopurine (6-MP or purinethol). Mercaptopurine is an anticancer and immunosuppressive drug also used to treat non-Hodgkin's lymphoma, Crohn's disease, and polycythemia vera.
Thiopurine methyltransferase (TPMT) methylates the thiopurines mercaptopurine and thioguanine, diverting the parent drug from metabolism to the active metabolites of thioguanine nucleotides (TGN). The consequence of methylation by TPMT is complicated by the fact that the methylated secondary metabolites may enhance antileukemic and immunosuppressive effects because of their direct inhibition of purine de-novo synthesis [1, 2] . TPMTactivity is inherited as a Mendelian trait, with common TPMT coding polymorphisms resulting in the classification of patients as homozygous deficient, heterozygous, or homozygous wild-type for TPMT genetic status. When routine doses of thiopurines are given to homozygous deficient patients, they have high levels of TGN and develop severe myelosuppression, which can be fatal [3] . The Clinical Pharmacogenetics Implementation Consortium recommends that patients with two nonfunctional TPMT alleles receive 10% or less of the thiopurine dose administered to patients with two functional TPMT alleles [4] . They also recommend starting therapy with thiopurines at 30-70% of the full dose in heterozygous patients, with monitoring of myelosuppression for further dose adjustments.
The murine model of Tpmt deficiency mimics the clinical toxicity and pharmacokinetics of thiopurines very well [5] , with higher levels of TGN metabolites and more severe toxicity in Tpmt knockouts (-/ -) versus heterozygous (+ / -) or wild-type (+/+) mice. However, the impact of homozygous deficiency or heterozygosity of Tpmt on the desired antileukemic efficacy of thiopurines is not known. Herein, we used this model system to evaluate antileukemic efficacy of mercaptopurine in Tpmt -/ -, + / -, and + / + mice. Given at a fixed low dose that is clinically relevant for TPMT -/ -patients, mercaptopurine significantly improved survival in Tpmt -/ -mice compared with untreated Tpmt -/ -mice and to mercaptopurine-treated Tpmt + / -and + / + mice. With higher doses of mercaptopurine, similar to what TPMT + / -or + / + patients would tolerate, leukemia-free survival increased to levels similar to Tpmt -/ -mice treated with the low dose.
Materials and methods

Mice
Tpmt-deficient mice were generated [5] and backcrossed to the 129X1/SvJ background (stock number 000691; Jackson Labs, Bar Harbor, Maine, USA) to create mice that were wild-type (+ / +), heterozygous (+ / -) or deficient (-/ -) with respect to Tpmt. Arf-null mice on a C57Bl/6 Â 129 mixed background [6] were backcrossed onto the 129X1/SvJ background for seven generations. For purposes of generating isogenic B-lineage ALL (see below), the two strains were crossed to generate mice that were wild-type with respect to Tpmt and null for Arf to provide bone marrow for generation of transplantable ALL. All recipient mice were wild-type with respect to Arf. Mice were bred in-house and maintained under specific pathogen-free conditions [7] . All experiments were conducted under the supervision of the facility's Institutional Animal Care and Use Committee (IACUC) according to an IACUC-approved protocol and requisite NIH guidelines. Trimethoprim/sulfamethoxazole (Septra pediatric suspension) was purchased from Hi-Tech Pharmacal (Amityville, New York, USA). A folic acid-deficient purified diet was purchased from Purina TestDiet (Richmond, Indiana, USA).
Tpmt activity assay
To confirm Tpmt phenotype, in terminal procedures, 1 ml blood was collected through cardiac puncture into tubes containing sodium heparin. Erythrocyte lysates were prepared and analyzed for Tpmt activity by a nonchelated radiochemical assay as described previously [5] . The assay is based on the conversion of mercaptopurine to radioactively labeled methylmercaptopurine with S-[methyl- Induction of acute lymphoblastic leukemia MSCV vectors coexpressing human BCR-ABL (p185) and luciferase [8] were packaged into replication-incompetent ecotropic virions as described [9] . Marrow extracted from the long bones of 129X1/SvJ Arf-null mice (Tpmt + / +) was suspended in vector-containing supernatant and plated to derive pro/pre-B cells on autologous stroma [10, 11] . Cells were maintained at 371C (8% CO 2 ) in RPMI with 10% fetal calf serum (Thermo Scientific Hyclone, Logan, Utah, USA), 4 mmol/l L-glutamine and 55 mmol/l 2-mercaptoethanol (Gibco, Grand Island, New York, USA). After 7-8 days of culture on autologous stroma, pro/pre-B cells were transferred to stromal-free culture for 2-3 days before cryopreservation in 90% FBS with 10% DMSO (Sigma Aldrich, St Louis, Missouri, USA) and storage in liquid nitrogen. Before injection, cells were thawed and recovered in culture for at least 48 h. 2000 Arf-null pro/pre-B cells bearing the p185 BCR-ABL fusion protein (confirmed to be coexpressing luciferase) were injected intravenously by tail vein into cohorts of healthy, unconditioned 8-10-week-old male and female 129X1/SvJ mice that were -/ -, -/ + , or + / + with respect to Tpmt and + / + with respect to Arf. Inactivation of Arf tumor suppression in donor leukemiainitiating cells enables only 20 such polyclonal cells to induce lethal ALL in unconditioned syngeneic recipients within 30 days [12] . The use of this model allowed us to study the impact of host genetics on drug treatment responses without any potentially confounding variables accompanying irradiation or other conditioning of recipient animals.
In-vivo treatment of leukemia Treatment was started 1 day after injection of leukemia cells. To mimic clinically relevant treatment regimens [13] , methotrexate was injected intraperitoneally at 1 mg/kg, once a week, as reported previously [5] . Mercaptopurine was administered in the drinking water. Assuming the mice drank 5 ml/day [14] , the mice received 2-2.5 mg/kg/day of mercaptopurine at the 10 mg/l dose, 10-12.5 mg/kg/day at the 50 mg/l dose, and 20-25 mg/kg/day at the 100 mg/l dose. Septra was included in the drinking water at 600 mg/l sulfamethoxazole and 120 mg/l trimethoprim (daily doses of 120-150 mg/kg and 24-30 mg/kg, respectively).
Mice were killed when they became moribund. Morbidity associated with ALL progression nearly always presented with hind limb paralysis, and often with a hunched back and/or domed head. Morbidity attributable to toxicity consisted of weight loss of more than 20% of maximum body weight, anemia (pale paws and ears), and lethargy, with low ALL burden confirmed by bioluminescence and pathologic examination of formalin-fixed tissues. Mice killed due to toxicity frequently were septic, with growth of Klebsiella pneumoniae, Kocuria kristinae, Lactococcus garvieae, Enterococcus casseliflavus, Yeast spp., or Corynebacterium urealyticum from aerobic blood cultures. Gram staining and analysis (Vitek II Compact System; BioMerieux, Durham, North Carolina, USA) were used to identify the organisms from sterile blood cultures on blood agar or MacConkey agar plates.
At the time of killing, blood was drawn by cardiac puncture while under isoflurane anesthesia into a tube with EDTA. Red blood cells were enumerated with a Coulter counter. The bones of the hind limbs were removed and the marrow was flushed with RPMI (Lonza BioWhittaker, Walkersville, Maryland, USA). The marrow was macerated over a sterile cell strainer (40 mm mesh) before counting cells with a hemacytometer. The spleen was excised and weighed. Tissues were fixed in 10% formalin, embedded in paraffin blocks, cut into 4 mm sections, and stained with hematoxylin and eosin.
Bioluminescent imaging
In-vivo imaging was performed with the Xenogen IVIS-200 (Caliper Life Sciences, Hopkinton, Massachusetts, USA) 3-5 min after intraperitoneal injection of 100 mg/kg D-luciferin (Caliper Life Sciences) [8] . The mice were anesthetized with isoflurane (2-3% in oxygen) before imaging. Images were acquired with small binning, beginning at 1-min exposure, or less if images were saturated. Images were analyzed with Living Image 3.1 software (Caliper Life Sciences). Total flux measurements (photons/s) were quantified over the whole animal.
Statistical analysis
Statistical analysis was done using Statistica 12 (Statsoft Inc., Tulsa, Oklahoma, USA). Survival curves were compared using the log-rank test. Other variables were compared using the Kruskal-Wallis test, CochranArmitage trend test or analysis of variance (ANOVA). P values less than 0.05 were considered statistically significant.
Results
Efficacy of low-dose mercaptopurine
Erythrocyte Tpmt activity differences among the Tpmt + / + , + / -, or -/ -129X1/SvJ mice were comparable with those recorded in patient erythrocytes [5] . After injection of 2000 BCR-ABL + Arf-null Tpmt + / + pre-B leukemia cells into male and female unconditioned, syngeneic mice, ALL was reproducibly lethal, with median survival (±SE) similar among Tpmt genotypes in untreated mice: 16 (±0.4) days for Tpmt + / + , 17 (±0.7) days for Tpmt + / -, and 18 (±0.4) days for Tpmt -/ - (Fig. 1a) . However, for the mice treated with low-dose mercaptopurine, the difference in 30-day leukemiafree survival was profound: 5% for Tpmt + / + mice, 47% for Tpmt + / -mice, and 85% for Tpmt -/ -mice (P = 5 Â 10 -8 , Cochran-Armitage trend test, Fig. 1a ). The cumulative leukemia-free survival of the Tpmt + / -mice treated with mercaptopurine was lower than the Tpmt -/ -mice (P = 0.001, log-rank) and trended higher than the Tpmt + / + mice (P = 0.075) treated with mercaptopurine, indicating a gene dosage effect for Tpmt on antileukemic efficacy. As expected, the Tpmt -/ -mice suffered more frequent drug-induced toxicity than the other cohorts.
Untreated leukemic mice had elevated white blood cell counts at the time of killing (median 66 000/ul). In mercaptopurine-treated mice, the white blood cell count at day 21 differed by Tpmt genotype, with Tpmt -/ -mice having the lowest, Tpmt + / + mice having the highest, and Tpmt + / -mice having an intermediate phenotype (Fig. 1b) (P < 0.000001) . The mercaptopurine-treated Tpmt -/ -mice killed due to leukemia had a smaller spleen size than all other groups (P < 0.000001, ANOVA), consistent with a superior antileukemic effect in the Tpmt -/ -mice.
Disease in mice recapitulated characteristics of human ALL, with infiltration of leukemia cells in the blood, lungs, liver, spleen, lymph nodes, bone marrow, meninges, and spinal column at the time of killing (Fig. 2) . Mice with hind limb paralysis often displayed leukemic cells infiltrating subdurally from the vertebral marrow, which compressed the nerves surrounding the spinal cord.
In-vivo bioluminescence was monitored once or twice weekly for assessment of leukemic burden. Whole-animal signal intensity was above 10 8 photons/s for all mice killed due to leukemia. Tpmt + / -mice tended to have lower bioluminescence than Tpmt + / + mice at day 21, while Tpmt -/ -mice had the lowest (Fig. 3a) , indicating that the low dose of mercaptopurine had a greater salutary effect on the Tpmt + / -mice than the + / + mice ( Fig. 3b , P = 0.00001, ANOVA). Thus, haploinsufficiency for Tpmt results in an antileukemic response intermediate between the -/ -and + / + mice, although survival of the Tpmt + / -mice was more similar to the Tpmt + / + mice than to the Tpmt -/ -mice (Fig. 1a) .
Efficacy of higher doses of mercaptopurine
To confirm that greater efficacy could be achieved with higher doses of mercaptopurine in Tpmt + / + mice, we increased the doses to 50 or 100 mg/l in groups of female mice. Antileukemic efficacy improved with higher doses of mercaptopurine, (Fig. 4a, 100 vs. 10 mg/l, P = 0.001). The bioluminescence signal at day 15 after injection of leukemia (14 days of treatment) showed a dosedependent effect: the leukemia burden was lowest in the mice receiving the highest dose of mercaptopurine ( Fig. 4b , P = 0.001, ANOVA). The cumulative leukemia-free survival of Tpmt + / + mice treated with 100 mg/ l mercaptopurine was equivalent to the Tpmt -/ -mice treated with 10 mg/l (P = 0.6, log-rank). The cumulative incidence of toxicity between these two groups was equivalent also (P = 0.7, log-rank).
Discussion
The relationship between thiopurine-induced acute toxicity and TPMT genotype is well-established [3, [15] [16] [17] [18] [19] [20] [21] ; however, the relationship between TPMT genotype and antileukemic efficacy is less clear. Clinically, patients with heterozygous TPMT status (one wild-type and one inactive allele) constitute B10% of most populations and have tolerance to thiopurines that is intermediate between those of homozygous deficient and homozygous wild-type patients, and intermediate starting doses of drug are recommended to minimize acute toxicity [4] . The impact of the host TPMT polymorphism on the desired antileukemic effects of thiopurines has been Efficacy of mercaptopurine in Tpmt-null mice Ramsey et al. 265 more difficult to assess clinically. Because TPMT homozygous deficient patients are so rare, the data on long-term cure rates in such patients are scarce, but it is clear that thiopurine doses must be reduced in such patients to avoid life-threatening toxicity, and anecdotally, such patients do not experience ALL relapse [16, 22] . Although some clinical studies indicate that patients who are heterozygous with respect to TPMT have lower ALL relapse rates when started at the usual high doses of mercaptopurine [18, 23, 24] , other studies show little impact of TPMT status [17, [25] [26] [27] , probably either because other elements of the ALL ); Tpmt + / -6-MP versus Tpmt + / + 6-MP (P = 0.075). (b) White blood cell counts at day 21 after injection in mercaptopurine-treated mice injected with leukemia, grouped by Tpmt genotype, show a gene dosage effect on antileukemic efficacy (P < 0.000001, Kruskal-Wallis). Boxes represent 25th-75th percentile, horizontal line represents the mean, whiskers indicate minimum to maximum values. Hematoxylin and eosin-stained tissue sections obtained at the time of killing from a representative mouse from all three genotypes for whom cause of death was leukemia (first three columns) or toxicity (right column). Mice were injected with 2000 Arf-null BCR-ABL + leukemia cells, treated with 10 mg/l mercaptopurine in the drinking water and 1 mg/kg/week methotrexate delivered intraperitoneally beginning day 1 after injection. Lung, Â 10. Tpmt + / + and + / -: alveolar septae thickened by leukemia cells; Tpmt -/ -leukemia: essentially normal. Tpmt -/ -toxicity: essentially normal. Liver, Â 10. Tpmt + / + and + / -: leukemia cells surround the blood vessels and are within sinusoids; Tpmt -/ -leukemia: moderate hepatocellular degeneration; Tpmt -/ -toxicity: mild degeneration. Kidney, Â 40. Tpmt + / + and + / -: essentially normal; Tpmt -/ -leukemia: few very small areas of necrotic tubules (circled area); this is more extensive in Tpmt -/ -toxicity (entire image). Spleen, Â 10. Tpmt + / + and + / -: almost completely replaced by leukemia cells; Tpmt -/ -leukemia: less severe replacement by leukemia cells; Tpmt -/ -toxicity: almost normal, slightly small spleen. Lymph nodes, Â 4. Tpmt + / + , + / -, and -/ -: almost completely replaced by leukemia cells. Tpmt -/ -toxicity: almost normal, slightly small lymph node. Bone marrow, Â 40. Tpmt + / + and + / -: almost completely replaced by leukemia cells, few megakaryocytes remaining; Tpmt -/ -leukemia: leukemia cells not as densely filling the marrow space, and a few foci of erythroid precursors remain (circled); Tpmt -/ -toxicity: severe marrow hypocellularity/toxicity. Brain, Â 10. Tpmt + / + , + / -, and -/ -leukemia: leukemia cells fill cranial marrow and extend into meninges; Tpmt -/ -toxicity: normal. Spine, Â 10. Tpmt + / + , + / -, and -/ -leukemia: leukemia cells in vertebral marrow. Epidural infiltration more severe in Tpmt + / + and + / -. Image not available for Tpmt -/ -toxicity.
Efficacy of mercaptopurine in
therapy overwhelmed the importance of thiopurines to cure, or because over the years, it has become more difficult to find clinical trials in which thiopurine doses were not decreased at least partly in response to data on TPMT status. In the current study, we were able to directly test the hypothesis that host Tpmt genotype influences the antileukemic efficacy of clinically relevant doses of mercaptopurine, even in the haploinsufficient state. We used a well-established murine model of BCR-ABL + ALL [8, 28, 29] and treated with clinically relevant doses of oral mercaptopurine. This approach allowed us to segregate the impact of Tpmt status of the host versus the leukemia, because the leukemic cells were wild-type with respect to Tpmt. Because the TPMT status of somatic and germline cells are the same within a patient [30] , such studies are only possible in genetically-tractable engineered murine models.
In clinical practice, the usual starting dosage of mercaptopurine has historically been driven by the fact that 90% of the population carries two wild-type alleles for TPMT, and thus a relatively high dose, often at 75 mg/m 2 /day is administered [3, 17, 23, 31] . Such a dose, however, is completely intolerable clinically in the 0.25% of the population who inherit two inactive TPMT alleles, a condition which produces human 'knock-outs' for TPMT, and which results in life-threatening myelosuppression [3] . Likewise, usual doses of mercaptopurine that are well tolerated by Tpmt + / + mice result in early toxic deaths in Tpmt -/ -mice [5] . Thus, our primary comparisons to test for the effect of Tpmt gene dosage on effectiveness was to use a dose low enough that all mice could tolerate, with 2-2.5 mg/kg/day for mice translating to B7.2-9 mg/m 2 for a child [32] , consistent with the low doses tolerated by homozygous deficient patients [3, 15, 19, 22, 33, 34] . However, we acknowledge that our dosing in the drinking water provides a more continuous source of mercaptopurine than the once per day dose normally used clinically, with some evidence that twice-daily doses result in lower methylated metabolites than once-daily dosing (albeit with no difference in TGN levels or outcome) [31, 35] . Tpmt + / -mice survived longer than Tpmt + / + mice and had an intermediate level of leukemia at day 21, indicating that haploinsufficiency for Tpmt confers greater antileukemic effect in response to a low fixed dose of mercaptopurine compared with that in Tpmt + / + mice. The dose that was low enough for the Tpmt -/ -mice to tolerate resulted in minimal antileukemic efficacy in the Tpmt + / + mice. This is consistent with clinical data showing that low TPMT activity was associated with a lower risk of relapse [23] , as well as with data showing that lowering doses in TPMT heterozygotes does not compromise cure rates [33, 36] , and reflects their reduced minimal residual disease burden when fixed thiopurine doses are given [37] . The higher toxicity in the Tpmt -/ -mice (at the same doses associated with greater antileukemic effect) illustrates the same difficulty faced clinically: doses must likely be pushed to the point of some myelosuppression to achieve optimal antileukemic effects. When the Tpmt + / + mice were treated with higher doses, they also experienced toxicity but displayed an improved antileukemic effect. These findings are consistent with recent clinical recommendations [4] to use three different starting doses for mercaptopurine based on TPMT status (wild-type > heterozygous > homozygous deficient), and then titrate to the desired degree of myelosuppression. Using this approach, cure rates in trials for treating childhood ALL were not compromised [33, 36] .
In summary, we have demonstrated that in an engineered and genetically defined murine leukemia model that mimics the human genetic germline polymorphism in TPMT, host Tpmt genotype and phenotype influenced the antileukemic efficacy of mercaptopurine, and that haploinsufficiency (heterozygous state equivalent for humans) confers a risk intermediate between homozygous wild-type and homozygous deficient status. These data are consistent with the increasingly accepted clinical practice of reducing the dose of thiopurines in TPMT + / -and -/ -patients to avoid host toxicity while maintaining antileukemic efficacy.
